Emcure Pharmaceuticals Secures Stock Exchange Approval for Promoter Group Reclassification

Emcure Pharmaceuticals , a leading Indian pharmaceutical company, has received approval from the National Stock Exchange (NSE) and BSE Limited for the reclassification of 14 promoter and promoter group members to the public category. This move, in accordance with SEBI Regulation 31A, marks a significant corporate action for the company.

Key Details of the Reclassification

The reclassification affects 14 individuals and entities, all of whom currently hold nil shareholding in the company. The list includes:

Name	Previous Category	New Category	Shareholding
Jashvantlal Hiralal Shah	Promoter Group	Public	NIL
Pravina J. Shah	Promoter Group	Public	NIL
Jigar J. Shah	Promoter Group	Public	NIL
Manish J. Shah	Promoter Group	Public	NIL
Akhil Bharadwaj	Promoter Group	Public	NIL
Malti Bharadwaj	Promoter Group	Public	NIL
Aditi Shrivastav	Promoter Group	Public	NIL
Madan Mohan Thapar	Promoter Group	Public	NIL
Ramni Thapar	Promoter Group	Public	NIL
Bhavna Battu	Promoter Group	Public	NIL
Akanksha Eye Clinic & Nursing Home	Promoter Group	Public	NIL
Kaja Investments LLC	Promoter Group	Public	NIL
Irrevocable Deed of Trust of Umakant Shah	Promoter Group	Public	NIL
The RAMNI and MADAN THAPAR Revocable Living Trust	Promoter Group	Public	NIL

Implications and Compliance

This reclassification aligns with the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015. The company received no-objection letters from both NSE and BSE on November 17, 2025, confirming the approval for this corporate action.

Recent Financial Performance

In addition to this corporate development, Emcure Pharmaceuticals has reported strong financial results for the second quarter of fiscal year 2026:

Revenue from operations grew by 13.4% year-on-year to INR 2,270.00 crores.
The domestic business saw a growth of 10.6% YoY, reaching INR 1,031.00 crores.
International markets maintained strong momentum with 15.8% YoY growth, totaling INR 1,238.00 crores.
Profit after tax showed robust growth of 24% YoY, reaching INR 251.00 crores.

Strategic Developments

The company has also made significant strides in its strategic initiatives:

Partnership with Novo Nordisk: Emcure Pharmaceuticals has entered into an agreement to distribute a second brand of semaglutide, Poviztra, in India. This move positions the company to capitalize on the growing obesity treatment market in the country.
Expansion in Europe: The company has launched Amphotericin B in Italy and plans to expand to other European markets like France and Germany in the coming months.
Biosimilars Progress: Emcure Pharmaceuticals has completed Phase III trials for Bevacizumab and is preparing to submit the file for regulatory approval.

These developments underscore Emcure Pharmaceuticals' commitment to growth and strategic positioning in both domestic and international markets. The company continues to focus on expanding its product portfolio and strengthening its market presence across various therapeutic areas.

Emcure Pharmaceuticals , a leading Indian pharmaceutical company, has reported robust financial results for the second quarter, along with a significant strategic partnership announcement.

Strong Financial Performance

Emcure delivered impressive quarterly results, with revenue growth of 13% year-on-year, reaching INR 2,270.00 crores. The company also achieved its highest quarterly profits to date, with a profit after tax (PAT) of INR 251.00 crores, representing a substantial 25% growth compared to the same period last year.

The strong performance was driven by solid growth across both domestic and international segments. The domestic business grew by 10.6% year-on-year to INR 1,031.00 crores, while the international markets maintained strong momentum, growing by 15.8% to INR 1,238.00 crores.

Segment-wise Performance

Segment	Revenue (INR Crores)	YoY Growth
Domestic	1,031.00	10.6%
International	1,238.00	15.8%
- Europe	444.00	22.7%
- Canada	348.00	17.5%
- Emerging Markets	446.00	8.6%

The company's performance in Europe was particularly noteworthy, with a strong growth of 22.7% year-on-year, reaching INR 444.00 crores. This growth was primarily driven by the ramp-up of Amphotericin B and benefits from the recently acquired Manx portfolio in the UK market.

Strategic Partnership with Novo Nordisk

Emcure Pharmaceuticals announced an exclusive partnership with Novo Nordisk to launch Poviztra (semaglutide) for obesity treatment in India. This partnership positions Emcure to target the estimated 250 million obese/overweight population in the country.

Key points of the partnership include:

Early market entry ahead of patent expiry
Access to Novo Nordisk's global product for the Indian market
Opportunity to shape the obesity treatment market in India

Satish Mehta, Managing Director & CEO of Emcure Pharmaceuticals, commented on the partnership, stating, "This indeed is a key initiative for us. We believe that having an early-mover advantage and an opportunity to shape this market will allow us to fully capture our share of that potential market that will play out over time."

Outlook and Future Plans

The company remains optimistic about its growth trajectory, with a focus on:

Expanding its presence in chronic disease segments
Leveraging partnerships with multinational companies
Continuing to invest in research and development
Exploring M&A opportunities in both domestic and international markets

Emcure's management has guided for base margin improvement of about 150 basis points for the current fiscal year, excluding the impact of recent in-licensing deals.

Conclusion

Emcure Pharmaceuticals' strong Q2 performance, coupled with its strategic partnership with Novo Nordisk, demonstrates the company's commitment to growth and innovation in the pharmaceutical sector. As the company continues to expand its presence in key therapeutic areas and markets, investors and industry observers will be keenly watching its progress in the coming quarters.